Emilie Branch

Using Predictive Intelligence to Uncover the Rare Disease Patient Journey

In this podcast interview, Dan Fisher, managing director and practice lead for IPM.ai, explains the use of artificial intelligence for stitching together key medical events that may happen over a rare and specialty disease patient’s lifespan that could predict whether or not a patient could be appropriate for a particular treatment or trial.

The rare disease patient journey can differ dramatically between disease states and individual patients, and the better the distinct patient point of view is understood, the more effective clinical trial recruitment or commercial effectiveness can be in reaching those patients.

IPM.ai collects data from 300 million patients which can help brands assess a patient population, accelerate clinical trial recruitment, and optimize commercial outcomes. By relying on real world health signals derived from claims data, machine learning, and artificial intelligence, it’s possible to create models that reveal the ideal de-identified patient and their healthcare ecosystem – regardless of their current diagnosis status.

Real-time alerts offer insight into potential patients who meet clinical criteria and their treating physicians. Using AI to identify patients who are likely to qualify for trial participation – as well as capturing patient race, ethnicity, and other demographics – creates a tremendous impact for funneling eligible patients. Then as commercialized products move to maturity, identifying those patients lost through conventional methods of HCP targeting and other patient level data applications adds value.

Listen below to learn about more use cases for applying patient findings to accelerate commercialization impact.

Using ML/AI to Find the Right Patients at the Right Time: A Conversation with AVEO Oncology

By: Dan Fisher, Principal, IPM.ai

Ganesh Rajaratnam, Senior Director of Commercial Operations,...

IPM.ai Recognized as One of the World’s Most Innovative Companies in 2022 by Fast Company

IPM.ai’s transformative approach to patient-finding for specialty and rare conditions captures the...

Ron Elwell, CEO and Founder of IPM.ai Wins MM+M’s Pinnacle Award

By: Dan Fisher, Principal, IPM.ai

Ron Elwell, CEO and founder of IPM.ai is a proud recipient of ...

Utilizing Augmented Intelligence to Drive Optimal Decisions Throughout the Specialty and Rare Disease Product Lifecycle

By: Dan Fisher, Principal, IPM.ai

Life sciences and healthcare companies that set out to pioneer...

A New Reference Model for Clinical Study Recruitment

By: Dan Fisher, Principal, IPM.ai

Conventional clinical study recruitment methods for rare diseases...

Real Chemistry's IPM.ai Expands Partnership with Datavant

San Francisco – Aug. 19, 2021 – Real Chemistry’s IPM.ai, the leader in uncovering undiagnosed and...

IPM.ai's Clinical Trial Recruitment Solution Featured in MM&M

By: Dan Fisher, Principal, IPM.ai

Allison Rhee of MM&M reports on IPM.ai's answer to patient...

IPM.ai Accelerates the Clinical Study and Commercialization of Precision Medicine

Targeted Approach Optimizes Clinical Study Recruitment of Medically-Eligible Patients Affected by...

Using Non-Traditional Data to Unlock Disease Insights & Improve Outcomes

By: Dan Fisher, Principal, IPM.ai

Though it’s not often discussed, the most difficult aspect of...